Design Therapeutics Income Statement (2020-2026) | DSGN

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & Cost
Revenue (Quarter)
Interest income
Interest Income - Total (Quarter)
3.29M3.25M3.21M3.04M2.70M2.49M2.31M2.17M2.07M
Interest expenses
Interest Income - Net (Quarter)
3.29M3.25M3.21M3.04M2.70M2.49M2.31M2.17M2.07M
Operating Items
Research & Development (Quarter)
5.03M8.54M7.34M8.76M11.29M14.30M14.26M15.73M17.06M13.26M11.01M9.80M10.52M11.88M12.16M15.38M15.74M14.59M-45.60M14.38M
Wages, Salaries and Other (Quarter)
0.04M0.10M0.22M0.22M0.23M0.26M0.25M0.26M3.66M3.75M3.64M4.38M4.40M4.16M4.60M4.79M
Selling, General & Administrative (Quarter)
2.66M2.80M3.79M4.61M4.34M4.89M5.14M5.92M5.53M5.57M4.11M4.60M4.53M4.37M4.54M5.04M5.83M0.06M4.74M5.33M
Other Operating Expenses (Quarter)
4.66M59.03M
Operating Expenses (Quarter)
7.69M11.34M11.13M13.37M15.64M19.19M19.39M21.65M22.60M18.82M15.12M14.40M15.04M16.25M16.69M20.42M21.57M19.31M18.17M19.71M
Operating Income (Quarter)
-7.69M-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-14.40M-15.04M-16.25M-16.69M-20.42M-21.57M-19.31M-18.17M-19.71M
EBIT (Quarter)
-7.69M-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-14.40M-15.04M-16.25M-16.69M-20.42M-21.57M-19.31M-18.17M-19.71M
Non-operating items
Interest & Investment Income (Quarter)
3.29M3.25M3.21M3.04M2.70M2.49M2.31M2.17M2.07M
Other Non Operating Income (Quarter)
0.05M0.02M0.06M0.10M0.64M1.49M2.05M2.36M2.66M3.03M3.28M3.29M3.25M3.21M
Non Operating Income (Quarter)
0.05M0.02M0.06M0.10M0.64M1.49M2.05M2.36M2.66M3.03M5.66M3.29M2.21M2.27M2.64M2.54M2.74M2.27M2.19M2.40M
Net income details
EBT (Quarter)
-7.69M-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-11.11M-11.79M-13.04M-13.65M-17.71M-19.08M-17.00M-16.00M-17.64M
Profit After Tax (Quarter)
-7.64M-11.32M-11.06M-13.27M-15.00M-17.70M-17.34M-19.29M-19.94M-15.79M-11.84M-11.11M-11.79M-13.04M-13.65M-17.71M-19.08M-17.00M-16.00M-17.64M
Income from Continuing Operations (Quarter)
-7.69M-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-11.11M-11.79M-13.04M-13.65M-17.71M-19.08M-17.00M-16.00M-17.64M
Consolidated Net Income (Quarter)
-7.69M-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-11.11M-11.79M-13.04M-13.65M-17.71M-19.08M-17.00M-16.00M-17.64M
Income towards Parent Company (Quarter)
-7.69M-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-11.11M-11.79M-13.04M-13.65M-17.71M-19.08M-17.00M-16.00M-17.64M
Net Income towards Common Stockholders (Quarter)
-7.69M-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-11.11M-11.79M-13.04M-13.65M-17.71M-19.08M-17.00M-16.00M-17.64M
Additional items
EPS (Basic) (Quarter)
-0.14-0.21-0.20-0.24-0.27-0.32-0.31-0.35-0.36-0.28-0.21-0.20-0.21-0.23-0.24-0.31-0.34-0.30-0.27-0.29
EPS (Weighted Average and Diluted) (Quarter)
-0.14-0.21-0.20-0.24-0.27-0.32-0.31-0.35-0.36-0.28-0.21-0.20-0.21-0.23-0.24-0.31-0.34-0.30-0.27-0.29
Shares Outstanding (Weighted Average) (Quarter)
55.08M55.16M45.94M55.51M55.59M55.65M55.71M55.91M55.93M55.95M55.98M56.49M56.52M56.56M56.59M56.76M56.81M56.95M57.33M61.43M
Shares Outstanding (Diluted Average) (Quarter)
36.46M55.16M45.94M55.51M55.59M55.78M55.71M55.91M55.95M55.99M55.98M56.49M56.52M56.62M56.59M56.76M56.81M56.95M57.33M61.43M
EBITDA (Quarter)
-7.65M-11.31M-11.30M-14.34M-15.99M-19.25M-16.84M-17.92M-19.95M-15.07M-10.50M-11.33M-11.84M-11.91M-16.69M-17.74M-21.57M-19.31M-18.17M-19.71M